Heron Therapeutics (NASDAQ:HRTX - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, March 11th. Analysts expect Heron Therapeutics to post earnings of ($0.03) per share and revenue of $37.37 million for the quarter. Heron Therapeutics has set its FY 2025 guidance at EPS.Persons that are interested in registering for the company's earnings conference call can do so using this link.
Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.05. The business had revenue of $40.78 million during the quarter, compared to analyst estimates of $37.37 million. On average, analysts expect Heron Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Heron Therapeutics Price Performance
HRTX stock traded up $0.13 during mid-day trading on Wednesday, reaching $2.42. 1,440,209 shares of the company's stock were exchanged, compared to its average volume of 1,869,271. The company has a market cap of $367.88 million, a price-to-earnings ratio of -13.36 and a beta of 1.55. Heron Therapeutics has a 12-month low of $1.04 and a 12-month high of $3.93. The stock's 50 day moving average is $1.80 and its 200 day moving average is $1.73.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on HRTX shares. Needham & Company LLC reissued a "buy" rating and issued a $4.00 price target on shares of Heron Therapeutics in a research note on Friday, February 28th. StockNews.com lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday.
Check Out Our Latest Research Report on HRTX
Heron Therapeutics Company Profile
(
Get Free Report)
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Further Reading
Before you consider Heron Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.
While Heron Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
